Global Infantile Spasms Therapeutics Market 2017-2021

  • ID: 4032436
  • Report
  • Region: Global
  • 73 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Anavex Life Sciences
  • Catalyst Pharmaceuticals
  • GW Pharmaceuticals
  • H. Lundbeck
  • INSYS Therapeutics
  • ORPHELIA Pharma
  • MORE
About Infantile Spasms Therapeutics

An infantile spasm is a particular type of seizure found in an epilepsy syndrome of infancy and childhood. It is also known as a West syndrome. The onset of infantile spasm is usually found in the first year of life between four months and eight months of age. The condition constitutes 2% of childhood epilepsies and 25% of epilepsies with onset in the first year of life. There are around 2,000-4,000 new cases observed in the US each year. The overall long-term prognosis for infantile spasms patients is poor. It has been found that 50%-70% of infantile spasms patients develop other seizure types and 18%-50% will develop Lennox-Gastaut syndrome (LGS) or other forms of symptomatic generalized epilepsy.

Analysts forecast the global infantile spasms therapuetics market to grow at a CAGR of 10.16% during the period 2017-2021.

Covered in this Report:

The report covers the present scenario and the growth prospects of the global thoracic surgery market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of infantile spasms therapuetics.

The Market is Divided Into the Following Segments Based on Geography:

Americas
APAC
EMEA

Global Infantile Spasms Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years.

The report also includes a a discussion of the key vendors operating in this market.

Key Vendors:

H. Lundbeck
Mallinckrodt Pharmaceuticals
INSYS Therapeutics

Other Prominent Vendors:

Anavex Life Sciences
Catalyst Pharmaceuticals
GW Pharmaceuticals
ORPHELIA Pharma
Retrophin
Valerion Therapeutics

Market Drivers:

Major drugs launch expected in 2017-2021
For a full, detailed list, view the full report

Market Challenges:

Growing usage of seizure management devices, a threat to drug therapies
For a full, detailed list, view the full report

Market Trends:

Development of devices and smartphone apps to detect seizures and track medications
For a full, detailed list, view the full report

Key Questions Answered in this Report:
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Anavex Life Sciences
  • Catalyst Pharmaceuticals
  • GW Pharmaceuticals
  • H. Lundbeck
  • INSYS Therapeutics
  • ORPHELIA Pharma
  • MORE
Part 01: Executive summary

Part 02: Scope of the report
Market overview
Top-vendor offerings

Part 03: Market research methodology
Research methodology
Economic indicators

Part 04: Introduction
Key market highlights

Part 05: Infantile spasm: Overview

Part 06: Market landscape
Global infantile spasms therapeutics market
Five forces analysis

Part 07: Market segmentation by dosage form
Solid
Liquid

Part 08: Market segmentation by ROA
Oral
Parenteral

Part 09: Geographical segmentation
Infantile spasms therapeutics market in Americas
Infantile spasms therapeutics market in EMEA
Infantile spasms therapeutics market in APAC

Part 10: Market drivers
Major drugs launch expected in 2017-2021
Growing scientific advancements in diagnostics
Special regulatory designations

Part 11: Impact of drivers

Part 12: Market challenges
Growing usage of seizure management devices, a threat to drug therapies
Limited patient population
Moderate pipeline

Part 13: Impact of drivers and challenges

Part 14: Market trends
Development of devices and smartphone apps to detect seizures and track medications
Alternate drugs fill the gap
Reformulation of marketed drugs

Part 15: Vendor landscape
Competitive scenario
Other prominent vendors

Part 16: Key vendor analysis
H. Lundbeck
Mallinckrodt Pharmaceuticals
INSYS Therapeutics

Part 17: Appendix
List of abbreviations

Part 18: Extras

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Snapshot of global infantile spasms therapeutics market 2016
Exhibit 03: Market overview of global infantile spasms therapeutics market
Exhibit 04: Opportunity analysis in developed and emerging markets
Exhibit 05: Global infantile spasm therapeutics market 2016-2021 ($ millions)
Exhibit 06: Approved infantile spasms therapeutics
Exhibit 07: Key customer segments of global infantile spasms therapeutics market
Exhibit 08: Five forces analysis
Exhibit 09: Segmentation of global infantile spasms therapeutics market by dosage form
Exhibit 10: Segmentation of global infantile spasms therapeutics market by ROA
Exhibit 11: Market share of global infantile spasms therapeutics market by ROA
Exhibit 12: Snapshot of global infantile spasms therapeutics market by geography
Exhibit 13: Global infantile spasms therapeutics market segmentation by geography 2016-2021 ($ millions)
Exhibit 14: Overview of infantile spasms therapeutics disease market in Americas
Exhibit 15: Market scenario in Americas
Exhibit 16: Healthcare system in US: Before and after reforms in ACA
Exhibit 17: Orphan drug development and regulatory challenges in America
Exhibit 18: Incentives provided for orphan drugs by US regulation
Exhibit 19: Infantile spasms therapeutics disease market in Americas 2016-2021 ($ millions)
Exhibit 20: Overview of infantile spasms therapeutics market in EMEA
Exhibit 21: Percentage share of epilepsy drugs market in EMEA by geography 2015
Exhibit 22: Market scenario in EMEA
Exhibit 23: Incentives provided for orphan drugs by EU regulation
Exhibit 24: Infantile spasms therapeutics market in EMEA 2016-2021 ($ millions)
Exhibit 25: Overview of infantile spasms market in APAC
Exhibit 26: Market scenario in APAC
Exhibit 27: Incentives provided for orphan drugs by Japanese regulation
Exhibit 28: Incentives provided for orphan drugs by Australian regulation
Exhibit 29: Infantile spasms therapeutics market in APAC 2016-2021 ($ millions)
Exhibit 30: CP-115 target indications
Exhibit 31: Clinical trial information for cannabidiol
Exhibit 32: Impact of drivers
Exhibit 33: Pipeline for infantile spasms therapeutics market
Exhibit 34: Pipeline molecules being developed for the treatment of infantile spasms disease
Exhibit 35: Impact of drivers and challenges
Exhibit 36: Impact of trends in global infantile spasms therapeutics market
Exhibit 37: Competitive structure analysis of global infantile spasm therapeutics market 2016
Exhibit 38: Geographical presence of key vendors
Exhibit 39: H. Lundbeck: Key highlights
Exhibit 40: H. Lundbeck: Strength assessment
Exhibit 41: H. Lundbeck: Strategy assessment
Exhibit 42: H. Lundbeck: Opportunity assessment
Exhibit 43: Mallinckrodt Pharmaceuticals: Profile
Exhibit 44: Mallinckrodt Pharmaceuticals: Strength assessment
Exhibit 45: Mallinckrodt Pharmaceuticals: Strategy assessment
Exhibit 46: Mallinckrodt Pharmaceuticals: Opportunity assessment
Exhibit 47: INSYS Therapeutics: Key highlights
Exhibit 48: INSYS Therapeutics: Strength assessment
Exhibit 49: INSYS Therapeutics: Strategy assessment
Exhibit 50: INSYS Therapeutics: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Anavex Life Sciences
  • Catalyst Pharmaceuticals
  • GW Pharmaceuticals
  • H. Lundbeck
  • INSYS Therapeutics
  • ORPHELIA Pharma
  • MORE
Global Infantile Spasms Therapeutics Market 2017-2021

Key players in the global infantile spasms therapeutics market: H. Lundbeck, Mallinckrodt Pharmaceuticals, and INSYS Therapeutics

Other Prominent Vendors in the market are: Anavex Life Sciences, Catalyst Pharmaceuticals, GW Pharmaceuticals, ORPHELIA Pharma, Retrophin, and Valerion Therapeutics

Commenting on the report, an analyst said: “The new trend observed in the infantile spasms market is the development of seizure alert devices that detects the seizure and notifies it to the physician, through alarms, phone calls, or text messages. SmartMonitor has developed a watch, SmartWatch, which should be worn 24 hours a day to detect any seizures. If it detects any seizures, it immediately sends out an alert warning to the caregivers/physicians. The device is now available only in the US. Also, Empatica has developed another smart watch, Embrace, which monitors the physiological stress, arousal, sleep, and physical activity of the individual. Apart from this, a smartphone application EpDetect has been developed, which exploits advanced signal processing to detect seizures. Once a seizure is detected, the application will inform the caregiver about the status of the patient along with the global positioning system (GPS) location. Similarly, BioLert has also developed EpiLert, which is an alert device with GPS and text messaging systems.”

According to the report, special regulatory designations such as fast track designations and orphan drugs designation assigned to the drugs by the US FDA and the EMA help in the faster entry of these drugs into the market. Fast track designations are assigned to the drugs used in the treatment of serious conditions with high unmet need prevailing in the market. Similarly, orphan drug designations are assigned for the drugs used in the treatment of rare diseases. These designations help in the faster approval process for the drugs and help in early entry into the market.

Further, the report states that orphan diseases such as infantile spasms disease have a lower incidence and prevalence rate than other diseases. According to the research studies published in 2015, the disease affected about one in 2,000-4,000 live births and approximately 10,000-20,000 infants were afflicted globally. Limited patient population restricts the clinical trial evaluation of drug candidates under development for the treatment of orphan indications. Drugs tested in these trials also fail to provide statistically significant results, even if they are efficacious and highly safe for consumption. Also, limited enrollment for clinical trials increases the occurrence of post-marketing adverse events. Clinical trials of new drugs and already available drugs also require large treatment populations. Drug manufacturers and researchers are also not able to recover their R&D expenses of the drugs and generate profits because of the limited patient population.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • H. Lundbeck
  • Mallinckrodt Pharmaceuticals
  • INSYS Therapeutics
  • Anavex Life Sciences
  • Catalyst Pharmaceuticals
  • GW Pharmaceuticals
  • ORPHELIA Pharma
  • Retrophin
  • Valerion Therapeutics
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll